MAXIMIZE
BRONCHODILATION...1,2*
Primary endpoint: 150-mL increase from baseline in predose FEV1 at Week 24 vs placebo (P<0.0001) in Trial 11,2†
BEVESPI AEROSPHERE is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms.
*Improvements in lung function, including predose FEV1† and peak FEV1 ,‡ relative to its individual components and placebo in two 24-week pivotal trials
Primary endpoint: Change from baseline in morning predose FEV1 at Week 241,2
Secondary endpoint: Mean change from baseline in peak FEV1 within 2 hours post-dose at Week 241,2
Secondary endpoint: Time to onset of action on Day 11,2
In separate Phase IIIb Trials: Through the breathing cycle3,4



All study treatments administered BID.
All study treatments administered BID.
All study treatments administered BID.
- There was also an increase from baseline in predose FEV1 at Week 24 for BEVESPI AEROSPHERE vs glycopyrrolate 18 mcg (59 mL) and formoterol fumarate 9.6 mcg (64 mL) (both P<0.0001).1,2 Statistically significant improvement in morning predose FEV1 was also demonstrated in Trial 21,2
- Adverse reactions with BEVESPI AEROSPHERE with a ≥2% incidence and more common than placebo were urinary tract infection and cough1†
- *Improvements in lung function relative to its individual components and placebo in two 24-week pivotal trials.
All study treatments administered BID.
- Secondary endpoint: In Trial 1, there were significant improvements from baseline at Week 24 in peak FEV1 for BEVESPI AEROSPHERE vs glycopyrrolate 18 mcg BID, formoterol fumarate 9.6 mcg BID, and placebo (P<0.0001 for all).1,2 Statistically significant improvement in peak FEV1 was also demonstrated in Trial 21,2‡
- Adverse reactions with BEVESPI AEROSPHERE with a ≥2% incidence and more common than placebo were urinary tract infection and cough1
- *Improvements in lung function relative to its individual components and placebo in two 24-week pivotal trials.
All study treatments administered BID.
- In Trial 1, the mean increase in FEV1 at 5 minutes after the first dose vs placebo (n=172) was 187 mL for BEVESPI AEROSPHERE (n=418), 44 mL for glycopyrrolate 18 mcg (n=363), and 184 mL for formoterol fumarate 9.6 mcg (n=366). The mean increase in FEV1 at 120 minutes after the first dose vs placebo (n=218) was 260 mL for BEVESPI AEROSPHERE (n=523), 136 mL for glycopyrrolate 18 mcg (n=448), and 229 mL for formoterol fumarate 9.6 mcg (n=441) (P<0.0001 for all)1,2
- Statistically significant improvement in FEV1 at 5 minutes was also demonstrated in Trial 21,2‡
- Adverse reactions with BEVESPI AEROSPHERE with a ≥2% incidence and more common than placebo were urinary tract infection and cough1
- *Improvements in lung function relative to its individual components and placebo in two 24-week pivotal trials.1,2

BEVESPI AEROSPHERE is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms.
FROM EXPIRATION…
Achieved ~300 mL improvement in peak FEV1 vs placebo3
Two separate Phase IIIb clinical trials evaluated the efficacy and safety of BEVESPI compared with placebo (Study A, n=35; Study B, n=75)3
- Primary endpoint: Mean improvements in FEV1 AUC0-24 on Day 29 for BEVESPI vs placebo were 249 mL and 265 mL (for Study A and Study B, respectively; both P<0.0001)4§
- Secondary endpoint: Mean changes from baseline in peak FEV1 on Day 29 (evening) for BEVESPI vs placebo were 293 mL and 337 mL (for Study A and Study B, respectively; P<0.0001)3
…THROUGH INSPIRATION
Achieved a 381 mL improvement in peak inspiratory capacity vs placebo3
- Secondary endpoint (continued): Mean improvements in peak IC from baseline on Day 29 (evening) for BEVESPI vs placebo were 381 mL (19.4%) and 312 mL (16.5%) (for Study A and Study B, respectively; both P<0.0001)4,5||¶
- Adverse events were numerically similar across treatment arms3
All study treatments were administered BID.